The 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of Rheumatic Diseases Symposium session titled, Updates on Vasculitis provided an overview of the latest information on vasculitis diagnosis and treatment.
Implementation of the G2211 add-on code for evaluation and management services is included in the CY 2024 Medicare Physician Fee Schedule, barring further delays. Ask your lawmakers to support timely implementation and patient access to complex care.
Science involves reading and writing as much as conducting experiments, says David S. Pisetsky, MD, PhD. No matter what discoveries are made in the lab, if they can’t be communicated well, how can they be used to advance the field and benefit patients? Dr. Pisetsky, the founding physician editor of The Rheumatologist, a professor of…
This session (12S114) at ACR Convergence 2023 will review the diagnostic approach to nonradiographic axial spondyloarthritis, with an emphasis on the role of imaging and recognition of its mimics. For your review—or a preview if you plan to catch the session on demand—our article will capture the highlights from Lianne Gensler, MD, Mark Hwang, MD,…
In this session at ACR Convergence 2023 (15W112), Ursula Fearon, PhD, Christopher Ritchlin, MD, MPH, and Jose Scher, MD, will highlight recent work that describes key processes in the pathophysiology of psoriatic arthritis, including perturbations in immune and stromal cells and the microbiome. Watch for our article for a snapshot of what these experts have…
The AMA’s Physician Practice Information Survey is seeking updated data on practice costs to inform Medicare physician payment. If your practice receives a request to participate, complete this important survey to help ensure accurate payment.
Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
From Oct. 15–Nov. 15, all donations to RheumPAC will be amplified by matching contributions, so it’s the best time to make your yearly investment. Donors above the silver level will be invited to a special event at ACR Convergence 2023.
The long-awaited list of the first 10 Part D drugs to be included in the new Medicare Price Negotiation process includes the commonly prescribed rheumatology drugs Enbrel and Stelara. Initial negotiations with the drug manufacturers will begin this fall.
In late September, 80 rheumatologists, rheumatology professionals and patients living with rheumatic disease convened in Washington, D.C., for the ACR’s annual Advocates for Arthritis conference, where they marshaled in support of legislation that would reduce current barriers to care for patients.